高级检索
当前位置: 首页 > 详情页

Thoracic perfusion of Esculentoside A-loaded thermosensitive hydrogel for the treatment of malignant pleural effusion in lung cancer

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Clinical Trial Centre, Department of Biotherapy, Department of Medical Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China [2]Department of Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China [3]Department of Integrated Traditional Chinese and Western Medicine, Cancer Hospital, University of Electronic Science and Technology of China, School of Medicine, Chengdu 610041, China [4]Department of Oncology, Fourth West China Hospital, Sichuan University, Chengdu 610041, China [5]West China School of Basic Medical Science and Forensic Medicine, Sichuan University, Chengdu 610065, China
出处:
ISSN:

关键词: Temperature-sensitive hydrogel Localized drug delivery Malignant pleural effusion Esculentoside A Thoracic perfusion Tumour-associated macrophages

摘要:
Malignant pleural effusion (MPE) is a common complication of advanced malignancy with a median survival of less than 5 months. Intrapleural injection is the main treatment for MPE, but there are problems such as the concentration of drugs not being durable and stable in the thoracic cavity, limiting therapeutic efficacy, rapid metabolism of drugs leading to systemic toxicity, a single mechanism of drug. Esculentoside A (EsA) exhibits multi-targeted effects that are potentially valuable to improve the immunosuppressive microenvironment in the thoracic cavity and suppress the development of MPE. But the toxicity and short half-life of EsA severely limit its use. We have developed an EsA delivery system based on a temperature-sensitive hydrogel (PLEL) for local treatment of MPE by intrapleural injection. The EsA/PLEL hydrogel supported slow-release of EsA and maintained a stable intrathoracic drug concentration, which not only significantly inhibited the progression of MPE and prolonged survival, but also reduced the side effects of EsA. We found that downregulating of CXCL1/ CXCL2/CXCL3-CXCR2 axis expression to reduce tumour-associated macrophages (TAMs) infiltration and tumour angiogenesis was a potential molecular mechanism for EsA/PLEL hydrogel to control lung cancer MPE. Therefore, this EsA/PLEL hydrogel delivery system has high potential for intrapleural injection therapy of MPE.

基金:
语种:
WOS:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 1 区 材料科学
小类 | 1 区 工程:化工 1 区 工程:环境
最新[2025]版:
大类 | 1 区 材料科学
小类 | 1 区 工程:化工 1 区 工程:环境
JCR分区:
出版当年[2024]版:
Q1 ENGINEERING, CHEMICAL Q1 ENGINEERING, ENVIRONMENTAL
最新[2024]版:
Q1 ENGINEERING, CHEMICAL Q1 ENGINEERING, ENVIRONMENTAL

影响因子: 最新[2024版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2024版]

第一作者:
第一作者机构: [1]Clinical Trial Centre, Department of Biotherapy, Department of Medical Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China [2]Department of Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:59490 今日访问量:1 总访问量:4869 更新日期:2025-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号